Navigation Links
Ernst Mayr's theory illustrated in genetic epidemiology studies

The late, famed evolutionary biologist Ernst Mayr's theory of genetic revolution , introduced in 1954, remains controversial to this day and has many detractors.

Mayr believed that genes interacted with one another, and that this genetic interaction in turn led to an interaction of natural selection with genetic drift that could cause genetic revolution ?new directions of evolutionary change.

Detractors of the theory object to what they consider the random nature of genetic drift.

But an evolutionary and population biologist at Washington University in St. Louis says that Mayr's theory has been illustrated nicely in recent years in human genetic epidemiology and population biology studies.

Alan R. Templeton, Ph.D., Washington University professor of biology in Arts & Sciences, said that there is an extensive documentation of genetic interaction over the past few years including his own genetic epidemiology studies of coronary artery disease (CAD).

"These recent results really show that Mayr's ideas were correct," said Templeton. "His theory has been empirically supported very well."

But first, the background. Mayr thought that founder events were very important in the origins of new species. These occur when a very small population of a species gets established in a new area. Because the population is very small, there is a lot of genetic randomness, and there is only a subset of the genetic variation of the ancestral population, and the frequencies of different kinds of genes can be changed dramatically.

Mayr also believed that there is lots of interaction between genes, so that when the frequency of one gene changes randomly, that causes a different suite of interactions to occur so that natural selection will drive the founder population in a different direction. He saw a very strong interaction between natural selection and random forces in a founder population.

"Mayr felt that the inte
'"/>

Source:Washington University in St. Louis


Page: 1 2 3 4

Related biology news :

1. Study casts doubt on Snowball Earth theory
2. Free-energy theory borne out in large-scale protein folding
3. New evidence supports century-old theory of cancer spread
4. Pitt professors theory of evolution gets boost from cell research
5. Why nerve cells work faster than the theory allows
6. Mayo Clinic researchers challenge sepsis theory
7. Methane-belching bugs inspire a new theory of the origin of life on Earth
8. New dyslexia theory blames noise
9. Hofmeyr skull supports the Out of Africa theory
10. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
11. Scientists detect probable genetic cause of some Parkinsons disease cases
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Ernst Mayr theory illustrated genetic epidemiology studies

(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Although the soluble factor TGF-beta has been shown to suppress ... breast cancer, high levels of TGF-beta during the later stages ... study using human breast cancer samples and mice, which appears ... January print issue of the Journal of Clinical Investigation, indicates ...
... successfully tested two candidate vaccines that may eventually be ... Their findings are published in the December 15 issue ... , Barney S. Graham, MD, PhD, and colleagues from ... in Maryland, the Fred Hutchinson Cancer Research Center in ...
... the University of Rochester may have answered one of ... neurons, which are responsible for our crystal-clear thoughts, seem ... November issue of Nature Neuroscience, the Rochester study shows ... signals to represent the ambiguities of the real world--and ...
Cached Biology News:Progress made in HIV vaccine development 2Mysterious 'neural noise' actually primes brain for peak performance 2Mysterious 'neural noise' actually primes brain for peak performance 3
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Calif., Jan. 22 Abaxis, Inc.,(Nasdaq: ABAX ), ... scheduled a conference call to discuss its,financial results for ... 2007. The call will be at 4:15 p.m. ET, ... 356-5706 or (706) 643-0580 to access the,conference call, or ...
... 8:30 a.m. EST at ... http://www.isispharm.com , ... ) announced today that Abbott is,investing up to $40 million in ... further develop the Ibis T5000(TM),Biosensor System, which offers a unique solution ...
... Marker Precision and ... Simultaneous Diagnostic Monitoring MUKILTEO, Wash. ... CBMX ) and Clarient, Inc. (Nasdaq: CLRT ),today ... a novel genomics-based cancer test called HemeScan(TM), a,comprehensive test related ...
Cached Biology Technology:Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 3Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 2CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 3CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 5CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 6
Mouse BLC/BCA 1 - 10kDa...
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Biology Products: